GSK vows to disclose payments to docs; details to come

Share this article:
GlaxoSmithKline plans to disclose payments to US physicians and impose a cap of $150,000 per year, per doctor, but details of the disclosure scheme are still being worked out.

GSK CEO Andrew Witty outlined the cap-and-publish policy to The Financial Times earlier in the week, saying that: “It's appropriate that we have a limit on what we pay. In the past, whatever has happened has happened, but in the future there will be strict adherence to these caps, which will be clearer to everybody.

Pressed for specifics, GSK said in a statement that it is “committed to making information about physician payments publicly available in the US. We are urgently undertaking a review of our internal processes to determine the best way to efficiently and accurately collect this information. We will be putting a process in place to ensure this information can be reported as soon as possible.”

The company's payments to Emory University's Dr. Charles Nemeroff, a prominent psychiatrist, were the subject of a recent investigation by Sen. Charles Grassley's Committee on Finance. Nemeroff resigned his position as chair of the university's psychiatry department after it was revealed that he had underreported fees from GSK.

Earlier this month, it was reported that the Dutch health inspectorate raided the offices of GSK and Sanofi-Aventis over alleged payments to physicians advising the government on health policy issues – including vaccinating girls against cervical cancer. GSK makes the Cervarix HPV vaccine, while Sanofi is handling European commercialization of Merck's Gardasil.

GSK noted that the disclosure policy, which would apply only to payments to US physicians, is irrelevant to the Dutch investigation.

Last month, Lilly announced it would disclose payments to physicians. In August, GSK said it would publish information on its CME grants, as Lilly and other companies had done.
Share this article:

Email Newsletters

More in News

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.

GSK, Novartis, Lilly play musical chairs

GSK, Novartis, Lilly play musical chairs

The three drugmakers rearranged part of the pharma universe Tuesday with a string of pipeline-altering deals.

Valeant bids $47B for Allergan

Valeant bids $47B for Allergan

The deal would bring Allergan's Botox and Juvederm under the same roof as Restylane.